공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

부신백질 디스트로피 : 파이프라인 리뷰

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 361622
페이지 정보 영문 110 Pages
가격
US $ 2,000 ₩ 2,367,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,735,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,102,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


부신백질 디스트로피 : 파이프라인 리뷰 Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 110 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

부신백질 디스트로피는 많은 경우 남성에게 일어나는 장애로, 주로 신경계와 부신에 영향을 미칩니다. 부신은 신장 위에 있는 작은 선입니다. 무베타 지질단백혈증은 부신백질 디스트로피(부신 척수 뉴로파시/X연관 부신백질 디스트로피)의 일종이며, 바센-코르츠바이크증후군이라고 불립니다. 장으로부터 음식의 지방을 완전하게 흡수할 수 없는 가족 내에서 발병하는 희귀질환입니다. 이 질환은 리포단백질을 만들도록 몸에 명령을 하는 유전자의 결함에 기인한 것입니다. 시간이 흐름에 따라 척추 만곡, 근력 저하, 시력 저하 등의 증상이 나타납니다. 치료에는 지용성 비타민을 함유하고 있는 비타민을 대량으로 이용합니다.

부신백질 디스트로피(Adrenoleukodystrophy)에 대한 치료제 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 프로파일, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 정리하여 전해드립니다.

서론

  • 조사 범위

부신백질 디스트로피 개요

치료제 개발

  • 파이프라인 제품 개요
  • 기업별 파이프라인
  • 대학/연구기관에서 개발된 파이프라인
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개발 참여 기업

  • bluebird bio Inc
  • MedDay SA
  • Minoryx Therapeutics sl
  • Pfizer Inc
  • ReceptoPharm Inc
  • Viking Therapeutics Inc

약제 프로파일

휴지 상태인 프로젝트

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

LSH 17.08.02

List of Tables

List of Tables

  • Number of Products under Development for Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Applied Genetic Technologies Corp, 2021
  • Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Ashvattha Therapeutics LLC, 2021
  • Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Autobahn Therapeutics Inc, 2021
  • Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by bluebird bio Inc, 2021
  • Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Celularity Inc, 2021
  • Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Imstem Biotechnology Inc, 2021
  • Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by MedDay SA, 2021
  • Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Minoryx Therapeutics sl, 2021
  • Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by NeuroVia Inc, 2021
  • Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Orpheris Inc, 2021
  • Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Poxel SA, 2021
  • Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by SwanBio Therapeutics Ltd, 2021
  • Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Viking Therapeutics Inc, 2021
  • Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Dormant Projects, 2021
  • Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adrenoleukodystrophy - Drugs In Development, 2021, provides an overview of the Adrenoleukodystrophy (Genetic Disorders) pipeline landscape.Adrenoleukodystrophy is a disorder that occurs most often in males. It mainly affects the nervous system and the adrenal glands, which are small glands located on top of each kidney. Abetalipoproteinemia is also a kind of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Bassen-Kornzweig syndrome is a rare disease passed down through families in which a person is unable to fully absorb dietary fats through the intestines. The disease is caused by a defect in gene that tells the body to create lipoproteins. It is sympotomized by curvature of spine, muscle weakness, decrease of vision over time. Treatment involves large doses of vitamin supplements containing fat-soluble vitamins.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Adrenoleukodystrophy - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Adrenoleukodystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Adrenoleukodystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 4, 5 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 1 and 2 molecules, respectively.

Adrenoleukodystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Adrenoleukodystrophy (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Adrenoleukodystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Adrenoleukodystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Adrenoleukodystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Adrenoleukodystrophy (Genetic Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Adrenoleukodystrophy (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Adrenoleukodystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Overview
  • Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Therapeutics Development
  • Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Therapeutics Assessment
  • Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Companies Involved in Therapeutics Development
  • Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Drug Profiles
  • Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Dormant Projects
  • Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Discontinued Products
  • Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q